Preclinical studies indicate that inhibiting SMO can prompt the shift of basal cell carcinoma to squamous cell carcinoma by promoting c-FOS activation of the EGFR/RAS/MAPK pathway. This evidence concerns the gene SMO and squamous cell carcinoma.